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Starting in January 1994, the new editor of Elsewhere will be Dr. Jake Liang. We warmly welcome him. I have 
been editor of this section for the last three years. It has been an interesting experience. This section allows the 
editor to select the articles and reviewers and thus to imprint a very personal character on the material published. 
In my case, I have been very fortunate to work on these endeavors with a group of individuals who provided their 
time, effort and article assessment to this group enterprise. In particular, I would like to recognize and thank Drs. 
Rebecca Van Dyke, Richard Moseley, Michael Lucey, Kenneth Lown, Paul Watkins, Peter Traber and Michael 
McDonnell at the University of Michigan for their continuous support and guidance. Also, I have had the invaluable 
collaboration of Diana Drescher and, lately, Brenda Vibbart, who put together each issue, arranged permissions and 
contacted reviewers. Finally, I would like to thank Dr. Paul Berk and Michelle Britton for their support, as well 
as Kerry Carlyle at Mosby. 
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HEPATOCYTE APOPTOSIS: IS TRANSFORMING 
Oberhammer FA, Pavelka M, Sharma S, Tietenbacher 
R, Purchio AF, Bursch W, Schulte-Hermann R. In- 
duction of apoptosis in cultured hepatocytes and in 
regressing liver by transforming growth factor pl .  Proc 
Natl Acad Sci USA 1992;89:5408-5412. 
GROWTH FACTOR-B1 THE KISS OF DEATH? 
ABSTRACT 
In previous studies hepatocytes undergoing cell 
death by apoptosis but not normal hepatocytes in rat 
liver showed immunostaining for transforming growth 
factor p1 (TGF-p1). Staining was much stronger with 
antibodies recognizing the pro-region of TGF-p1 than 
the mature peptide itself. Therefore we investigated 
the ability of both forms of TGF-Pl to induce apoptosis 
in primary cultures of rat hepatocytes. Mature TGF-PI 
induced rounding up of the cells and fragmentation 
into multiple vesicles. As revealed by the DNA-specific 
stain H33258, the chromatin of these cells condensed 
and segregated into masses at the nuclear membrane; 
this was obviously followed by fragmentation of the 
nucleus. Ultrastructurally the cytoplasm was well pre- 
served, as demonstrated by the presence of intact cell 
organelles. These features strongly suggest the occur- 
rence of apoptosis. Quantification of nuclei with con- 
densed chromatin revealed that mature TGF-p1 was 
30-fold more effective than the TGF-P1 latency-asso- 
ciated protein complex. Finally, we administered 
TGF-p1 in uiuousing an experimental model in which 
regression of rat liver was initiated by a short pre- 
ceding treatment with the hepatomitogen cyproterone 
acetate. Two doses of TGF-Pl, each 1 nM/kg, augmented 
the incidence of apoptotic hepatocytes 5-fold. Equi- 
molar doses of TGF-Pl latency-associated protein 
complex were ineffective. These studies suggest that 
TGF-P1 is involved in the initiation of apoptosis in the 
liver and that the mature form of TGF-pl is the active 
principle. 
COMMENTS 
Recent studies on the mechanisms of liver growth 
have emphasized the notion that hepatic growth regu- 
lation depends on a balance between stimulatory and 
suppressor factors (1). As remarkable as the growth of 
the liver after partial hepatectomy is, equally amazing is 
the cessation of growth when optimal liver mass is 
regained. Yet the mechanisms that determine growth 
termination have not been as intensively studied as the 
events that trigger regeneration. The beginning and end 
of the process are, however, likely linked and represent, 
respectively, disruption of the equilibrium between liver 
mass and body mass and restoration of the normal 
equilibrium. Various factors and events have been 
suggested as signals for growth termination; they may 
involve, among others, transforming growth factor 
(TGF)Pl activation, release of other inhibitors such as 
activin, reexpression of tumor-suppressor genes, atten- 
uation of proliferative stimuli, activation of tran- 
scription factors that regulate liver-specific genes, rees- 
tablishment of cellhell contact between hepatocytes and 
the deposition of laminin after cells undergo one round 
of replication. Any one of these mechanisms could 
conceivably be put in motion by an alert signaling system 
that somehow senses the functional performance of the 
liver in relationship to the body’s needs. It is relatively 
easy to imagine what this system needs to do when 
hepatic tissue deficit occurs, but what is to be done when 
the liver acquires excess functional mass? When this 
happens, to put it crudely, word goes out that cells must 
be killed or forced to commit suicide so that order - that 
is, the appropriate liver massbody mass ratio - can be 
restored. 
Increases in liver mass above normal in the absence of 
a compensatory response to tissue deficit can be brought 
about by drugs and other agents that stimulate liver 
metabolism, by nutritional shifts, by orthotopic trans- 
plantation of a large liver and by heterotopic transplan- 
tation. In all of these cases, the excess mass does not 
persist when the cause of the increase is removed or in 
the months after transplantation. It is most likely that 
the mechanism of tissue regression in these conditions 
involves the selective death of hepatocytes by apoptosis. 
This type of cell death, in contrast to necrosis, occurs in 
individual, nonclustered cells. It shows characteristic 
patterns of chromatin condensation morphologically 
and formation of DNA ladders detected on gel electro- 
phoresis analysis indicative of DNA cleavage at  internu- 
cleosomal sites (2). Most important, apoptosis is con- 
sidered a “programmed” process - that is, it may re- 
quire gene activation for its triggering. Apoptosis may be 
controlled by hormones, growth factors, cytokines, 
calcium and other agents, and in B lymphocytes and 
other cells it is strongly inhibited by the expression of the 
bcl-2 gene, which was originally cloned as a chromo- 
somal translocation breakpoint in follicular B-cell lym- 
phomas (3). 
